Abstract
Current analgesics, such as opioids and nonsteroidal anti-inflammatory drugs (NSAIDs), are largely refinements of approaches available for more than 100 years and have critical liabilities and limitations. A number of new molecular targets for analgesia have been proposed in recent years, including the neuronal nicotinic acetylcholine receptor (nAChR). Agonists at neuronal nAChRs have antinociceptive effects in a variety of preclinical pain models. Moreover, nicotine can decrease experimentally-induced pain in humans without disrupting normal tactile sensation. These data from both experimental animals and humans suggest that compounds targeting neuronal nAChRs may represent a new class of analgesic agents. In this paper, we provide brief overviews of the physiology of pain, the animal models used to assess potential analgesics preclinically, and the biology of nAChRs. We then provide a review of preclinical data on the antinociceptive effects of a variety of neuronal nAChR agonists and a discussion of potential mechanisms, including evidence that antinociception is mediated by activation of brainstem nuclei with descending inhibitory inputs to the spinal cord. An evaluation of the clinical potential of this approach must also consider potential side effects. Undesirable side effects of nicotine are well known, but as we will discuss in detail, these effects are not produced by all neuronal nAChR agonists and the existence of neuronal nAChR subtypes may provide a basis for separating therapeutic effects from toxicities.
Keywords: Nicotinic Acetylcholine, nAChR agonists, Analgesics
Current Topics in Medicinal Chemistry
Title: Nicotinic Acetylcholine Receptor Agonists: A Potential New Class of Analgesics
Volume: 4 Issue: 3
Author(s): M.W. Decker, L.E. Rueter and R.S. Bitner
Affiliation:
Keywords: Nicotinic Acetylcholine, nAChR agonists, Analgesics
Abstract: Current analgesics, such as opioids and nonsteroidal anti-inflammatory drugs (NSAIDs), are largely refinements of approaches available for more than 100 years and have critical liabilities and limitations. A number of new molecular targets for analgesia have been proposed in recent years, including the neuronal nicotinic acetylcholine receptor (nAChR). Agonists at neuronal nAChRs have antinociceptive effects in a variety of preclinical pain models. Moreover, nicotine can decrease experimentally-induced pain in humans without disrupting normal tactile sensation. These data from both experimental animals and humans suggest that compounds targeting neuronal nAChRs may represent a new class of analgesic agents. In this paper, we provide brief overviews of the physiology of pain, the animal models used to assess potential analgesics preclinically, and the biology of nAChRs. We then provide a review of preclinical data on the antinociceptive effects of a variety of neuronal nAChR agonists and a discussion of potential mechanisms, including evidence that antinociception is mediated by activation of brainstem nuclei with descending inhibitory inputs to the spinal cord. An evaluation of the clinical potential of this approach must also consider potential side effects. Undesirable side effects of nicotine are well known, but as we will discuss in detail, these effects are not produced by all neuronal nAChR agonists and the existence of neuronal nAChR subtypes may provide a basis for separating therapeutic effects from toxicities.
Export Options
About this article
Cite this article as:
M.W. Decker , L.E. Rueter and R.S. Bitner , Nicotinic Acetylcholine Receptor Agonists: A Potential New Class of Analgesics, Current Topics in Medicinal Chemistry 2004; 4 (3) . https://dx.doi.org/10.2174/1568026043451447
DOI https://dx.doi.org/10.2174/1568026043451447 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Adaptogens—History and Future Perspectives
Adaptogens are pharmacologically active compounds or plant extracts that are associated with the ability to enhance the body’s stability against stress. The intake of adaptogens is associated not only with a better ability to adapt to stress and maintain or normalise metabolic functions but also with better mental and physical ...read more
AlphaFold in Medicinal Chemistry: Opportunities and Challenges
AlphaFold, a groundbreaking AI tool for protein structure prediction, is revolutionizing drug discovery. Its near-atomic accuracy unlocks new avenues for designing targeted drugs and performing efficient virtual screening. However, AlphaFold's static predictions lack the dynamic nature of proteins, crucial for understanding drug action. This is especially true for multi-domain proteins, ...read more
Artificial intelligence for Natural Products Discovery and Development
Our approach involves using computational methods to predict the potential therapeutic benefits of natural products by considering factors such as drug structure, targets, and interactions. We also employ multitarget analysis to understand the role of drug targets in disease pathways. We advocate for the use of artificial intelligence in predicting ...read more
Challenges, Consequences and Possible Treatments of Anticancer Drug Discovery ll
The use of several compounds has been the subject of increasing interest in phytochemistry, biochemistry, and other fields of research at the chemistry-biology-ecosystems interface. In spite of the continued search for new anticancer drugs, cancer remains a leading cause of death. Cancer mortalities are expected to increase to 12.9 million, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recombinant Antibodies in Cancer Therapy
Current Protein & Peptide Science [11C]Meta-Hydroxyephedrine PET/CT
Current Radiopharmaceuticals An Efficient Organocatalyst for Environmentally benign Synthesis of Pyranopyrazole Derivatives in Aqueous Medium
Letters in Organic Chemistry Obstructive Sleep Apnoea Syndrome and Diabetes. Fortuitous Association or Interaction?
Current Diabetes Reviews Pharmacological Treatment of Vagal Hyperactivity, a Rare but Potentially Fatal Cause of Sudden Cardiac Death
Mini-Reviews in Medicinal Chemistry Fresh Frozen Plasma Administration in the NICU: Evidence-based Guidelines
Current Pediatric Reviews Novel Immunotherapies for Hematological Malignancies
Current Molecular Pharmacology Redefining the Role of Long-Acting Phosphodiesterase Inhibitor Tadalafil in the Treatment of Diabetic Erectile Dysfunction
Current Diabetes Reviews Ligands and Therapeutic Perspectives of Adenosine A2A Receptors
Current Pharmaceutical Design New Physiological Targets Within the Kidney for Antihypertensive Therapy
Drug Design Reviews - Online (Discontinued) Mitochondrial Biogenesis: Regulation By Endogenous Gases During Inflammation and Organ Stress
Current Pharmaceutical Design The Effect of Acute Hypoxia on Excitability in the Heart and the L-Type Calcium Channel as a Therapeutic Target
Current Drug Discovery Technologies Current Treatment of Autoimmune Blistering Diseases
Current Drug Discovery Technologies RAS in the Central Nervous System: Potential Role in Neuropsychiatric Disorders
Current Medicinal Chemistry Is Adrenaline Always the First Choice Therapy of Anaphylaxis? An Allergist-cardiologist Interdisciplinary Point of View
Current Pharmaceutical Design Diagnosis and Management of Hypertensive Emergencies Complicating Pregnancy
Current Women`s Health Reviews The RNA-Dependent-RNA Polymerase, an Emerging Antiviral Drug Target for the Hendra Virus
Current Drug Targets Patterns of Self-Medication with Medicinal Plants and Related Adverse Events - A South American Survey
Current Drug Safety Ketamine Metabolites-waiting in the Wings as Therapeutic Candidate for Depression?
Current Molecular Pharmacology New Antihypertensive Drugs Under Development
Current Medicinal Chemistry